English  |  正體中文  |  简体中文  |  总笔数 :2833128  
造访人次 :  34216468    在线人数 :  1711
教育部委托研究计画      计画执行:国立台湾大学图书馆
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
关于TAIR

浏览

消息

著作权

相关连结

"su w p"的相关文件

回到依作者浏览
依题名排序 依日期排序

显示项目 41-50 / 76 (共8页)
<< < 1 2 3 4 5 6 7 8 > >>
每页显示[10|25|50]项目

机构 日期 题名 作者
臺大學術典藏 2020-05-26T09:26:57Z A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies Lin C.-C;Su W.-C;Yen C.-J;Hsu C.-H;Su W.-P;Yeh K.-H;Lu Y.-S;Cheng A.-L;Huang D.C.-L;Fritsch H;Voss F;Taube T;Chih-Hsin Yang; Lin C.-C; Su W.-C; Yen C.-J; Hsu C.-H; Su W.-P; Yeh K.-H; Lu Y.-S; Cheng A.-L; Huang D.C.-L; Fritsch H; Voss F; Taube T; CHIH-HSIN YANG
臺大學術典藏 2020-05-25T07:35:22Z A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies Chia-Chi Lin; Su W.-C; Yen C.-J; Hsu C.-H; Su W.-P; Yeh K.-H; Lu Y.-S; Cheng A.-L; Huang D.C.-L; Fritsch H; Voss F; Taube T; Yang J.C.-H.
臺大學術典藏 2020-05-25T07:35:14Z Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial Aarts M.J.B; Erdkamp F.L.G; Blaisse R.J.B; Flores C.L.U; Cort?s L.V; Lee Y.-G; Kim Y.J; Rha S.Y; Ferrario C; Sengeloev L; Jensen N.V; Thibault C; Laguerre B; Joly F; Flechon A; Culine S; Becht C; Niegisch G; St?ckle M; Grimm M.-O; Gakis G; Schultze-Seemann W; Kalofonos H; Mavroudis D; Papandreou C; Karavasilis V; R?v?sz J; Geczi L; Rosenbaum E; Leibowitz-Amit R; Kejzman D; Sarid D; Scagliotti G.V; Bracarda S; Massari F; Osawa T; Miyajima N; Shinohara N; Fukuta F; Ohyama C; Obara W; Yamashita S; Tomita Y; Kawai K; Fukasawa S; Oyama M; Yonese J; Nagata M; Uemura M; Nishimura K; Kawakita M; Tsunemori H; Hashine K; Inokuchi J; Yokomizo A; Nagamori S; Lee H.J; Park S.H; Alekseev B; Necchi A; G?czi L; Ou Y.-C; Coskun H.S; Su W.-P; Hegemann M; Percent I.J; Lee J.-L; Tucci M; Semenov A; Laestadius F; Peer A; Tortora G; Safina S; del Muro X.G; Rodriguez-Vida A; Cicin I; Harputluoglu H; Widau R.C; Liepa A.M; Walgren R.A; Hamid O; Zimmermann A.H; Bell-McGuinn K.M; Powles T; Wong S.-L.S; Tan T.H; Hovey E.J; Clay T.D; Ng S.S.W; Rutten A; Machiels J.-P; Dumez H; Cheng S.Y.-S; Petrylak D.P; de Wit R; Chi K.N; Drakaki A; Sternberg C.N; Nishiyama H; Castellano D; Hussain S; Fl?chon A; Bamias A; Yu E.Y; van der Heijden M.S; Matsubara N; Vaishampayan U.; Aragon-Ching J; Tagawa S; Lawler W; Lowe T; Herms B; Hainsworth J; Cultrera J; Schwarz J; Flaig T; Pan C.X; Wojcik-Tomaszewska J; Tomczak P; Sikora-Kupis B; Schenker M; Herzal A.A; Udrea A.A; Karlov P; Fomkin R; Pulido E.G; Mignorance J.I.D; Gauna D.C; Rodr?guez-Vida A; Su Y.-L; Lin C.-L; Chia-Chi Lin; Yeh S.-P; ?i?in I; Erman M; Urun Y; Golovko Y; Bondarenko I; Sinielnikov I; Crabb S; Syndikus I; Huddart R; Sundar S; Chowdhury S; Sarwar N
臺大學術典藏 2020-05-25T07:35:03Z Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial Petrylak D.P; de Wit R; Chi K.N; Drakaki A; Sternberg C.N; Nishiyama H; Castellano D; Hussain S.A; Fl?chon A; Bamias A; Yu E.Y; van der Heijden M.S; Matsubara N; Alekseev B; Necchi A; G?czi L; Ou Y.-C; Coskun H.S; Su W.-P; Bedke J; Gakis G; Percent I.J; Lee J.-L; Tucci M; Semenov A; Laestadius F; Peer A; Tortora G; Safina S; Garcia del Muro X; Rodriguez-Vida A; Cicin I; Harputluoglu H; Tagawa S.T; Vaishampayan U; Aragon-Ching J.B; Hamid O; Liepa A.M; Wijayawardana S; Russo F; Walgren R.A; Zimmermann A.H; Hozak R.R; Bell-McGuinn K.M; Powles T; Wong S.-L.S; Tan T.H; Hovey E.J; Clay T.D; Wan Ng S.S; Rutten A; Machiels J.-P; Dumez H; Cheng S.Y.-S; Ferrario C; Sengeloev L; Jensen N.V; Thibault C; Laguerre B; Joly F; Culine S; Becht C; Niegisch G; St?ckle M; Grimm M.-O; Schwentner C.A; Schultze-Seemann W; Kalofonos H; Mavroudis D; Papandreou C; Karavasilis V; R?v?sz J; Rosenbaum E; Leibowitz-Amit R; Kejzman D; Sarid D; Scagliotti G.V; Bracarda S; Massari F; Osawa T; Miyajima N; Shinohara N; Fukuta F; Ohyama C; Obara W; Yamashita S; Tomita Y; Kawai K; Fukasawa S; Oyama M; Yonese J; Nagata M; Uemura M; Nishimura K; Kawakita M; Tsunemori H; Hashine K; Inokuchi J; Yokomizo A; Nagamori S; Lee H.J; Park S.H; Rha S.Y; Kim Y.J; Lee Y.-G; Vazquez Cort?s L; Lorena Urzua Flores C; Blaisse R.J.B; Erdkamp F.L.G; Aarts M.J.B; Wojcik-Tomaszewska J; Tomczak P; Sikora-Kupis B; Schenker M; Herzal A.A; Udrea A.A; Karlov P; Fomkin R; Gajate Borau P; Grande E; Delgado Mignorance J.I; Su Y.-L; Li J.-R; Lin C.-L; Chia-Chi Lin; Yeh S.-P; Erman M; Urun Y; Golovko Y; Bondarenko I; Sinielnikov I; Crabb S.J; Syndikus I; Huddart R; Sundar S; Chowdhury S; Sarwar N; Flaig T.W; Pan C.X; Schwarz J.K; Cultrera J.L; Acs P.I; Hainsworth J.D; Herms B.T; Lawler W.E; Lowe T.E.
臺大學術典藏 2020-05-25T06:52:08Z Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients Su W.-P;Wen C.-C;Hsiung C.A;Su I.-J;Cheng A.-L;Chang M.-C;Tsao C.-J;Kao W.-Y;Uen W.-C;Hsu C.-H;Yen-Shen Lu;Tien H.-F;Chao T.-Y;Chen L.-T;Whang-Peng J;Chen P.-J.; Su W.-P; Wen C.-C; Hsiung C.A; Su I.-J; Cheng A.-L; Chang M.-C; Tsao C.-J; Kao W.-Y; Uen W.-C; Hsu C.-H; YEN-SHEN LU; Tien H.-F; Chao T.-Y; Chen L.-T; Whang-Peng J; Chen P.-J.
臺大學術典藏 2020-05-25T06:51:54Z A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies Lin C.-C;Su W.-C;Yen C.-J;Hsu C.-H;Su W.-P;Yeh K.-H;Yen-Shen Lu;Cheng A.-L;Huang D.C.-L;Fritsch H;Voss F;Taube T;Yang J.C.-H.; Lin C.-C; Su W.-C; Yen C.-J; Hsu C.-H; Su W.-P; Yeh K.-H; YEN-SHEN LU; Cheng A.-L; Huang D.C.-L; Fritsch H; Voss F; Taube T; Yang J.C.-H.
臺大學術典藏 2020-04-28T07:25:19Z A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies Lin C.-C.;Su W.-C.;Yen C.-J.;Chih-Hung Hsu;Su W.-P.;Yeh K.-H.;Lu Y.-S.;Cheng A.-L.;Huang D.C.-L.;Fritsch H.;Voss F.;Taube T.;Yang J.C.-H.; Lin C.-C.; Su W.-C.; Yen C.-J.; CHIH-HUNG HSU; Su W.-P.; Yeh K.-H.; Lu Y.-S.; Cheng A.-L.; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; Yang J.C.-H.
臺大學術典藏 2020-04-10T12:51:27Z Gefitinib treatment for non-small cell lung cancer - A study including patients with poor performance status Su W.-P.;Yang C.-H.;Yu C.-J.;Shih J.-Y.;Chiun Hsu;Yang P.-C.; Su W.-P.; Yang C.-H.; Yu C.-J.; Shih J.-Y.; Chiun Hsu; Yang P.-C.
臺大學術典藏 2020-04-10T12:51:25Z Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer Gow C.-H.; Chiun Hsu; Chang G.-C.; Yang P.-C.; Su W.-P.; Lin C.-P.; Yang T.-Y.; Yu C.-J.; Chen K.-C.; Shih J.-Y.; Yang C.-H.; Yang C.-H.;Shih J.-Y.;Chen K.-C.;Yu C.-J.;Yang T.-Y.;Lin C.-P.;Su W.-P.;Gow C.-H.;Chiun Hsu;Chang G.-C.;Yang P.-C.
臺大學術典藏 2020-03-26T06:54:22Z Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer Wang C.-Y.; Chao T.-T.; Tai W.-T.; Chang F.-Y.; Su W.-P.; Chen Y.-L.; Chen P.-T.; Weng C.-Y.; ANG YUAN; Shiau C.-W.; Yu C.-J.; Chen K.-F.

显示项目 41-50 / 76 (共8页)
<< < 1 2 3 4 5 6 7 8 > >>
每页显示[10|25|50]项目